PET/CT

Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.

RSS icon
PET-CT imaging of 124-I evuzamitide and SPECT-CT imaging of 99mTc-p5+14 showed radiotracer uptake in both AL and ATTR amyloid throughout the myocardium. Emily B. Martin, Anne Kassira, Alan Stuckey, et al. A tale of two tracers - Amyloid imaging with investigational radiotracers iodine (124I) evuzamitide and 99mTc-p5+14 (AT-05). https://www.journalofnuclearcardiology.org/article/S1071-3581(25)00325-3/abstract.

Bayer expands into molecular imaging with cardiac amyloidosis tracer acquisitions

Bayer is acquiring two cardiac amyloidosis radiotracers from Attralus, one for PET and one for SPECT. The SPECT tracer is also a theranostic agent to both image and treat amyloidosis.

Sarah-Jane James, CT, MRI, molecular imaging senior market analyst for Signify Research, explains key trends in imaging systems she saw at the Radiological Society of North America (RSNA) 2025 meeting.

Key trends in medical imaging systems at RSNA 2025

Sarah-Jane James, imaging market analyst for Signify Research, discusses key trends in the specialty that she saw at the Radiological Society of North America's annual meeting. 

Positron NeuSight PET-CT 64 slice scanner

Positron raises $2M to expand PET-CT commercialization

The New York-based imaging company is now focused on expanding sales for the cost-effective PET-CT system it developed with Neusoft Medical Systems.

Thumbnail

Leading nuclear medicine organizations collaborate to streamline PET accreditation

The groups have jointly endorsed a unified framework “to standardize and harmonize quantitative PET imaging worldwide.”

Copper-based radiotracer excels at PSMA imaging

Copper-based PSMA radiotracer shines in clinical trial

The tracer's extended half-life of over three hours could make it a promising candidate for future prostate cancer diagnostics. 

Telix Pharmaceuticals

Telix says new kidney cancer imaging agent alters treatment plans for 50% of patients

The positive findings come after the U.S. Food and Drug Administration previously shared concerns related to sterility assurance issues during the drug’s production.

UCLA Health

UCLA launches ‘first of its kind’ new standalone Department of Nuclear Medicine and Theranostics

“Becoming an independent department elevates this work and strengthens UCLA’s role in shaping the future of precision health," said the department's new acting chairman. 

The new cardiac PET radiotracer flurpiridaz F-18 is posed to be a major game changer and will likely lead to increased adoption of cardiac PET.

Largest network of private cardiology groups in US to deploy GE HealthCare's cardiac PET tracer

One of the tracer’s more significant advantages is its extended half-life of 109 minutes—significantly longer than other currently available PET MPI imaging agents.

Displaying 9 - 16 of 170
Design by Adaptive Theme